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During an inflammatory state, functional myeloper-
oxidase (MPO) is released into the vessel as a result of
intravascular neutrophil degradation. One mecha-
nism of resulting cellular injury involves endothelial
internalization of MPO, which causes oxidative dam-
age and impairs endothelial signaling. We report the
discovery of a protein that facilitates MPO internaliza-
tion, cytokeratin 1 (CK1), identified using affinity
chromatography and mass spectrometry. CK1 inter-
acts with MPO in vitro , even in the presence of 100%
human plasma, thus substantiating biological rele-
vance. Immunofluorescent microscopy confirmed
that MPO added to endothelial cells can co-localize
with endogenously expressed CK1. CK1 acts as a scaf-
folding protein for the assembly of the vasoregulatory
plasma kallikrein-kinin system; thus we explored
whether MPO and high molecular weight kininogen
(HK) reside on CK1 together or whether they compete
for binding. The data support cooperative binding of
MPO and HK on cells such that MPO masked
the plasma kallikrein cleavage site on HK, and MPO-
generated oxidants caused inactivation of both HK
and kallikrein. Collectively, interactions between
MPO and the components of the plasma kallikrein-
kinin system resulted in decreased bradykinin
production. This study identifies CK1 as a facilitator
of MPO-mediated vascular responses and thus pro-
vides a new paradigm by which MPO affects vasoregu-
latory systems. (Am J Pathol 2007, 171:349–360; DOI:
10.2353/ajpath.2007.060831)
Vascular injury due to inflammation is caused by the
release of injurious radicals and proteins from granule
components of neutrophils and monocytes into the extra-
cellular space. MPO is one of the principal enzymes
stored in azurophilic granules of neutrophils and peroxi-
some-positive lysosomes of monocytes and comprises 5
and 1%, respectively, of the cells’ total protein.1 MPO
imparts its antimicrobial properties by converting hydro-
gen peroxide, generated by neutrophils during a respi-
ratory burst, into hypochlorous acid, a powerful oxidant
that readily reacts with adjacent thiol, disulfide, and
amino acid residues.2
Increased levels of MPO are detected in serum of
patients with inflammatory disease, suggesting that neu-
trophils aberrantly degranulate in the vascular lumen.3–7
Free MPO spilled into the vasculature interacts with en-
dothelial cells and contributes to endothelial dysfunc-
tion.8–10 Our previous explorations of this process indi-
cated that MPO is internalized by endothelial cells with a
resultant rise in intracellular oxidant radicals.11 Others
have extended these findings by demonstrating that
MPO transcytoses through the endothelium and concen-
trates in the subendothelial matrix.12 Internalized MPO
modulates vascular signaling and vasodilatory functions
by decreasing the bioavailability of nitric oxide via multi-
ple mechanisms.6,8 For example, hypochlorous acid can
chlorinate L-arginine, thus reducing functional substrate
for endothelial nitric-oxide synthetase, and substrate rad-
icals produced by MPO can catalytically consume nitric
oxide.6,8
As a continuation of our previous work, our aim was to
identify proteins on the endothelial cell surface that spe-
cifically interacted with MPO, with the goal of finding
proteins that facilitate its internalization. We have discov-
ered that cytokeratin 1 (CK1) is an endothelial binding
partner for MPO. CK1 is part of a possible endothelial
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receptor complex containing urokinase-like plasminogen
activator receptor (uPAR) and the receptor for the glob-
ular head of complement 1q protein (gC1qR). This mul-
tiprotein receptor complex is a platform for assembly and
activation of the vasoregulatory plasma kallikrein-kinin
system.13,14 Circulating high molecular weight kininogen
(HK) binds to this complex and serves as the endothelial
receptor for the zymogen prekallikrein. An endothelial
membrane- and matrix-associated enzyme, prolylcar-
boxypeptidase, activates prekallikrein, which then
cleaves the nonapeptide bradykinin from HK.15 Because
both MPO and HK interact with CK1, MPO might interfere
with the functionality of the kallikrein-kininogen system.
The results herein provide a novel layer of interaction
between MPO and endothelial vasoregulatory systems
that could potentiate vascular injury during inflammation.
Functional studies indicate that CK1 can facilitate inter-
nalization of MPO, and moreover, this interaction has the
potential to disrupt normal endothelial processes.
Materials and Methods
Cell Culture and Reagents
Cells
Human umbilical vein endothelial cells (HUVECs) and
endothelial growth medium (EGM) basal media with
Singlequot supplements were purchased from Cambrex
(East Rutherford, NJ). Cells were typically used between
passages 5 and 10. EA.hy926, an immortalized endothe-
lial hybridoma cell line, was kindly provided by Cora-Jean
Edgell, Ph.D. (University of North Carolina at Chapel Hill,
Chapel Hill, NC) and cultured in Gibco/Invitrogen (Carls-
bad, CA) Dulbecco’s modified Eagle medium with peni-
cillin-streptomycin and 10% fetal bovine serum. Both cell
lines were grown in a 5% CO2 humidified incubator.
EA.hy926 cells were used in addition to HUVECs in im-
munofluorescent co-localization studies and in internal-
ization blocking experiments. Reproducibility of the data
using two different endothelial cell lines lends confidence
in its validity and implies generality in endothelial
systems.
Antibodies
Mouse and rabbit anti-human MPO antibodies were
purchased from DAKO (Carpinteria, CA). An additional
mouse anti-human MPO antibody was purchased from
Abcam (Cambridge, MA). Mouse anti-proteinase 3 anti-
bodies were purchased from Lab Vision Neomarkers
(Fremont, CA) and Research Diagostics, Inc. (Concord,
MA). Rabbit anti-CK1 antibody was purchased from Co-
vance Research Products (Berkley, CA), and the mouse
pan-cytokeratin antibody (clone PCK-26) was from Sigma
(St. Louis, MO). Affinity-purified goat anti-CK1 antibody
was prepared as previously characterized.16,17 Normal
total IgG of all species was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Horseradish peroxi-
dase-conjugated secondary antibodies were purchased
from Chemicon (Temecula, CA), and Alexa Fluor 488-
and 569-conjugated secondary antibodies were pur-
chased from Invitrogen (Carlsbad, CA). Alkaline phos-
phatase-conjugated streptavidin was purchased from
Pierce (Rockford, IL). Alkaline phosphatase-conjugated
Affinipure F(ab)2 fragment donkey anti-mouse IgG was
from Jackson ImmunoResearch Laboratories (West
Grove, PA). The alkaline phosphatase substrate kit was
either from Bio-Rad Laboratories (Hercules, CA) or
Pierce.
Purified Proteins
MPO and catalase were purchased from Calbiochem
(San Diego, CA). Proteinase 3 was purchased from Weis-
lab AB (Lund, Sweden). Recombinant CK1 (rCK131) was
prepared as previously reported.17 Pooled human cyto-
keratins and L-methionine were purchased from Sigma.
High molecular weight kininogen, plasma kallikrein, fac-
tor XII (SA 27.77 U/mg), and high molecular weight
kininogen-deficient human plasma were purchased from
Enzyme Research Laboratories (South Bend, IN). PilB, a
methionine sulfoxide reductase derived from Neisseria
gonorrhoeae, was generously provided by Dr. Nathan
Brot at Cornell University, Joan and Sanford I. Weill Med-
ical College, New York, NY.
Immunoprecipitations of MPO and CK1
HUVEC lysates were prepared as either whole cell or
membrane fraction lysates. To prepare the whole cell
lysate, HUVECs were washed with ice-cold phosphate-
buffered saline (PBS) and scraped in lysis buffer [25
mmol/L HEPES, 12.5 mmol/L MgCl2, 150 mmol/L KCl,
0.5% Nonidet P-40, 1 mmol/L sodium orthovanadate, 50
mmol/L sodium fluoride, and Roche (Almeda, CA) com-
plete ethylenediaminetetraacetic acid proteinase inhibi-
tor cocktail] at 4°C. Glycerol was added to 10%. Lysates
were pooled and split evenly into three tubes. Insoluble
debris was centrifuged and separated from lysate. Mem-
brane fraction lysate was prepared using Pierce’s MEM-
PER isolation kit as instructed with the addition of sodium
fluoride, sodium orthovanadate, and the Roche protease
inhibitor cocktail. The pooled membrane fraction was
dialyzed in PBS  1% Nonidet P-40 overnight for 3
nights, changing the dialysate each night. Glycerol was
added to 10%, and the pooled lysate split evenly into
three tubes. Protein A/G beads (Pierce) and normal
mouse IgG were added to each tube for 1 hour at 4°C
and then centrifuged to preclear the lysate. Ten g of
purified proteinase 3 or MPO was added to the lysates for
5 hours at 4°C, and mouse anti-MPO or anti-PR3 antibod-
ies were added to the appropriate tubes overnight. Pro-
tein A/G beads were added to the tubes for 1 hour at 4°C.
The beads were washed with lysis buffer and PBS, and
any protein complexes were eluted from the beads di-
rectly in Laemmli buffer. The samples were subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) and then stained with Coomassie
Brilliant Blue R-250. Unique bands in the MPO immuno-
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precipitation lane were excised and analyzed by matrix-
assisted laser desorption ionization/time of flight at the
University of North Carolina’s Proteomics Core Facility
using methods published by Parker and colleagues.18
Mouse anti-MPO antibody (100 g) was immobilized
on Pierce’s AminoLink Plus coupling gel as instructed.
HUVECs were washed with ice-cold Hanks’ balanced salt
solution and scraped at 4°C into lysis buffer (formulation
above) containing 0.5% Triton X-100 and 10% glycerol.
The lysate was sheared with a 22-gauge needle and the
insoluble debris centrifuged and separated. The lysate
was split into two tubes, one of which received 2.5 g of
purified MPO. The tubes were rocked at 4°C for 3 hours,
after which immobilized mouse anti-MPO was added to
the tubes overnight. The gel-containing lysates were
spun and washed in Pierce’s Handee Cup spin columns
with 10 column volumes of lysis buffer and eluted using
the AminoLink plus kit. Laemmli buffer was added to
each elution fraction and the fractions were subjected to
SDS-PAGE and Western blot analysis.
Two g of purified MPO was mixed with either 2 g of
recombinant CK1, 2 g of recombinant control protein, or
nothing in IP buffer (25 mmol/L HEPES, 12.5 mmol/L
MgCl2, 150 mmol/L KCl, 0.5% Nonidet P-40, and 10%
glycerol) overnight at 4°C with constant mixing. Four g
of either mouse anti-MPO or mouse anti-pan CK antibody
was added to the mix, as well as antibody alone in IP
buffer, and allowed to mix overnight at 4°C. Protein A/G
beads (Pierce) were added for 1 hour and washed, and
protein complexes were eluted directly in Laemmli buffer.
Elutions were subject to SDS-PAGE and Western blot
analysis.
Enzyme-Linked Immunosorbent Assays
(ELISAs) Demonstrating MPO Binding to CK1
and HK
ELISA plates were coated with 5 g/ml of either rabbit
anti-CK1 or normal rabbit IgG overnight at 4°C. Wells
were blocked with a 0.2% fish gelatin buffer (150 mmol/L
NaCl, 50 mmol/L Tris base, 0.05% Tween 20, 0.2% fish
gelatin, and 0.02% sodium azide, pH 7.6) for 4 hours at
room temperature, and all subsequent steps were per-
formed in this blocking solution. CK1 was captured over-
night at 4°C from a mix of solubilized human keratins (10
g/ml) derived from human epidermis. Purified MPO was
presented to the captured CK1 at 5 g/ml at room tem-
perature for 4.5 hours. The wells were exposed to mouse
anti-MPO antibody at a 1:100 dilution and each of three
sera from patients with circulating MPO-specific anti-
neutrophil cytoplasmic autoantibodies diluted at 1:100 in
duplicate overnight at 4°C. The CK1-MPO complexes
were detected by alkaline phosphatase-conjugated sec-
ondary antibody incubation for 1 hour at room tempera-
ture followed by the addition of substrate. Plates were
read at 405 nm after 1 hour using a VERSAmax plate
reader (Molecular Devices, Sunnyvale, CA).
ELISA plates were coated with either rabbit anti-CK1
antibody or normal rabbit IgG at 5 g/ml overnight at 4°C.
The wells were blocked in a 1% fish gelatin buffer for 4
hours at room temperature and then exposed to a 10
g/ml solution of solubilized human keratins in blocking
buffer overnight at 4°C to capture CK1. Plasma was
obtained from healthy patients in Vacutainer tubes K3
ethylenediaminetetraacetic acid 12 mg (purple top) (Bec-
ton Dickinson, Franklin Lakes, NJ). Solutions of 0, 25, 50,
75, and 100% plasma were prepared with or without the
addition of 5 g/ml MPO. The plasma solutions were
prepared using 1% fish gelatin buffer that was drawn into
the Vacutainer tubes to keep the ethylenediaminetet-
raacetic acid concentration constant throughout this
stage of the experiment. The plasma solutions were
placed in the wells for 4 hours at room temperature. The
captured MPO was labeled with the DAKO mouse anti-
MPO antibody at a 1:100 dilution at 4°C overnight. The
next day, secondary antibody was applied for 1 hour at
room temperature followed by substrate. The plates were
read at 405 nm 3 hours after the addition of substrate.
ELISA plates were coated either with rabbit or mouse
anti-MPO antibody or with normal rabbit or mouse IgG at
5 g/ml overnight at 4°C. The wells were blocked with
0.2% fish gelatin buffer for 1 hour at room temperature,
and all subsequent steps were performed in the blocking
buffer. MPO was captured at 5 g/ml for 1 hour at room
temperature. Wells were washed thoroughly, and 2 g/ml
biotinylated HK was added with or without a 75-fold ex-
cess of unlabeled HK in duplicate. Unlabeled HK only
was also added to wells in duplicate. After 1 hour at room
temperature, the wells were washed, and alkaline phos-
phatase-conjugated streptavidin was added for an addi-
tional hour. After the addition of substrate for 1 hour, the
plate was read at 405 nm. Similar experiments were
conducted using ELISA plates directly coated with either
MPO or bovine serum albumin.
ELISA plates were coated with either rabbit anti-MPO
antibody or normal rabbit IgG (5 g/ml) overnight at 4°C.
The wells were blocked with 1% fish gelatin buffer for 2
hours at room temperature. HK-deficient plasma was
replenished with a physiological concentration (80 g/ml)
of biotinylated high molecular weight kininogen (bHK).
The HK-deficient plasma was added to the wells with or
without bHK overnight at 4°C. After thorough washing,
alkaline phosphatase-conjugated streptavidin was
added to the wells for 1 hour at room temperature. Sub-
sequently, substrate was applied, and the plate was
placed at 4°C overnight. Spectrophotometer readings
were taken at 405 nm after resting the plates at room
temperature for 6 hours.
Immunofluorescent Co-Localization of
MPO and CK1
EA.hy926 cells were plated on glass coverslips, grown to
90% confluence, washed, and treated with MPO (10
g/ml) for 10 minutes in serum-free Dulbecco’s modified
Eagle’s medium. The cells were washed in PBS, fixed in
4% paraformaldehyde, and permeabilized with acetone.
Goat serum was used as a block (at 10% in Tris-buffered
saline with 0.05% Triton X-100) and antibody dilution
buffer (at 1% in Tris-buffered saline with 0.05% Triton
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X-100), and the cells were labeled with rabbit anti-CK1
and mouse anti-MPO antibodies. Alexa Fluor-conjugated
secondary antibodies were used for detection: the Alexa
Fluor 488 was goat anti-rabbit, and the Alexa Fluor 568
was goat anti-mouse. The coverslips were mounted on
slides with anti-fade and analyzed using a LSM5 Pascal
confocal laser-scanning microscope (Zeiss, Thornwood,
NY) with the accompanying software suite.
HUVECs were plated to 90% confluence (140,000
cells per well) and allowed to attach overnight to 0.1%
gelatin-coated glass coverslips in 12-well culture dishes.
Cells were washed twice with prewarmed, phenol red-
free EGM basal media with or without 2% fetal bovine
serum, and MPO was added at 15 g/ml for 12 minutes
at 37°C. Cells were then placed on ice and washed in
ice-cold PBS and fixed in ice-cold 2% paraformaldehyde
for 45 minutes on ice. The wells were then washed and
permeabilized with ice-cold 1:1 methanol/acetic acid on
ice for 10 minutes. Goat serum was used as the blocking
agent (at 10% in Tris-buffered saline with 0.05% Triton
X-100) and the antibody dilution buffer (at 1% in Tris-
buffered saline with 0.05% Triton X-100). The coverslips
were blocked for 1 hour at room temperature. The cells
were then labeled with the Abcam mouse anti-MPO an-
tibody (1:250 dilution) for 1 hour at room temperature,
followed by rabbit anti-CK1 (1:80 dilution) in the same
conditions. Alexa Fluor-conjugated secondary antibodies
were used for detection: the Alexa Fluor 488 was goat
anti-rabbit, and the Alexa Fluor 568 was goat anti-mouse.
The secondary antibodies were prepared at a 1:500 di-
lution and applied simultaneously. The coverslips were
mounted on slides with anti-fade and analyzed using a
Zeiss LSM5 Pascal confocal laser-scanning microscope
with the accompanying software suite.
Antibody Blocking Experiments
EA.hy926 cells grown in 12-well culture dishes, or
HUVECs grown in six-well dishes, were washed with
serum-free, phenol red-free Dulbecco’s modified Eagle’s
medium. Cells were pretreated in the serum-free media
with blocking antibodies. One experiment used a block-
ing mix consisting of 16.67 g/ml goat-anti-CK1 (which
blocks HK binding to endothelial cells) and a 50-fold
molar excess of factor XII (which also binds CK1) for 45
minutes at 37°C.16 Other experiments used the pan-cy-
tokeratin antibody or normal mouse IgG at 16.67 g/ml
for 45 minutes at 37°C. MPO (0.5 to 2 g/ml) was added
subsequently to the cells in the presence of the blocking
antibodies for 10 minutes. The cells were washed with the
serum-free media and trypsinized. When the cells re-
leased from the plate, either trypsin-neutralizing solution
(Cambrex) or serum-containing medium was added, and
the cells were collected. The cells were processed using
the Caltag Laboratories Fix and Perm kit (Invitrogen) and
stained for MPO using the rabbit anti-MPO antibody in
conjunction with an Alexa Fluor 488 chicken anti-rabbit
secondary antibody. The stained cells were analyzed
using a FACScan flow cytometer linked to a CellQuest
software system (Becton-Dickinson Immunocytometry
Systems, San Jose, CA).
HK-Binding Studies on HUVECs
HUVECs were plated to confluence in EGM basal media
(without the Singlequot supplement) in 96-well tissue cul-
ture wells that were precoated with a 1% gelatin solution.
Eighteen to twenty-four hours after plating, the cells were
washed with a HEPES-carbonate buffer (154 mmol/L
NaCl, 5.6 mmol/L KCl, 3.4 mmol/L NaHCO3, 5.5 mmol/L
dextrose, 5 mmol/L HEPES, 2 mmol/L CaCl2, 1 mmol/L
MgCl2, and 0.1% gelatin, pH 7.4), and biotinylated HK
was added to the cells at 20 nmol/L in HEPES-carbonate
buffer either alone or in the presence of a 50-fold molar
excess of unlabeled HK or MPO for 30 minutes at 37°C.
Unbound proteins were washed away, and the cells were
treated with alkaline phosphatase-conjugated streptavi-
din at room temperature for 1 hour. The cells were
washed, the substrate was applied, and the absorbance
was read at 405 nm after 1 hour at room temperature.
Immunofluorescent Co-Localization of MPO and
HK on Endothelial Cells
HUVECs were grown to 80% confluence on 0.1% gelatin-
coated glass coverslips. Biotinylated HK (50 nmol/L) was
premixed with a fivefold molar excess of MPO in EGM
basal medium. The cells were gently washed with the
EGM basal medium and the protein mix added for 30
minutes at 37°C. Control groups included each protein
added individually or no protein. The cells were placed
on ice, washed thoroughly in ice-cold PBS, and then fixed
in 1.5% paraformaldehyde for 40 minutes at room tem-
perature. Some coverslips were dipped in acetone to
permeabilize the cells. The coverslips were blocked in
10% chicken serum for 45 minutes. Subsequent steps
were performed in 1% chicken serum for 1 hour at room
temperature in the order listed with thorough PBS washes
in between each step: Alexa Fluor 488-conjugated
streptavidin diluted 1:500, rabbit anti-MPO at a 1:2500
dilution, and Alexa Fluor 569 chicken anti-rabbit second-
ary antibody diluted 1:1500. The coverslips were then
mounted in anti-fade medium.
ELISA Measuring the Effects of MPO on
Bradykinin Production
To quantitate bradykinin released in the presence of
MPO, HK (50 nmol/L) was incubated with 5, 50, or 500
nmol/L MPO in PBS for 20 minutes at room temperature
in microcentrifuge tubes. Kallikrein (50 nmol/L) was
added to the mix for 20 minutes at room temperature,
and the samples were frozen at 80°C for future anal-
ysis. Samples were thawed and analyzed for bradyki-
nin release using Dainippon Pharmaceutical’s MAR-
KIT-M bradykinin ELISA kit (Osaka, Japan). Our
experimental samples were handled for analysis per
the manufacturer’s instructions specific to urine spec-
imens. Amount of reagents added was adjusted to
accommodate smaller volumes.
To measure the effect of the MPO-H2O2-Cl
 system
activity on bradykinin production, HK (50 nmol/L) was
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incubated with MPO (10, 50, or 250 nmol/L) and 0.45
mol/L H2O2 in PBS in the presence or absence of cata-
lase (10-fold molar excess to MPO) for 20 minutes at
room temperature in microcentrifuge tubes. L-Methionine
(100 mol/L) was added to the mix for 20 minutes to
quench HOCl activity. Kallikrein (50 nmol/L) was then
added for 20 minutes at room temperature, and the sam-
ples were frozen at 80°C for future analysis. Samples
were thawed and analyzed for bradykinin release using
the aforementioned bradykinin ELISA kit.
To determine the direct effects of HOCl on bradyki-
nin production, HK (50 nmol/L) was pretreated with
increasing concentrations of HOCl in PBS at room tem-
perature for 20 minutes in microcentrifuge tubes. A
20-fold excess of L-methionine (compared with HOCl
concentration) was added to the mix for an additional
20 minutes. Kallikrein was subsequently added to 50
nmol/L for 20 minutes at room temperature, and the
samples were frozen at 80°C for further analysis.
Bradykinin release was measured in the samples using
the bradykinin ELISA kit. The unknown values were
determined using a seven-point standard curve with an
R2 value of 0.95.
Kallikrein Protease Activity Assay
Kallikrein (50 nmol/L) was treated with HOCl or HOCl that
was preincubated with a 20-fold excess of L-methionine (to
quench oxidative properties) at varying concentrations in
microcentrifuge tubes for 15 minutes. L-Methionine was
subsequently added to those tubes that received non-
quenched HOCl. Samples were transferred to a 96-well
plate, and Chromogenix S-2303 plasma kallikrein-specific
chromogenic substrate (Diapharma, Westchester, OH) was
added and mixed, and OD 405 nm was read after 30
minutes of rocking at room temperature. Values were ad-
justed by subtracting background OD values of HOCl 
L-methionine without kallikrein.
Methionine Sulfoxide Reductase Assay
HK (50 nmol/L) was pretreated with 25 mol/L HOCl in PBS
for 20 minutes at room temperature, and unreacted HOCl
was quenched with 500 mol/L L-methionine (a 20-fold
molar excess) for an additional 20 minutes. PilB (50 nmol/L)
was added to the reaction mix in the presence of 15 mmol/L
Figure 1. CK1 and CK9 specifically bind MPO.
A: Coomassie-stained gel of immunopurified
MPO or proteinase 3 (PR3) complexes resolved
by SDS-PAGE. Mass spectrometry analysis of the
unique bands in the MPO-spiked membrane
fraction identified CK1 and CK9. The spectra are
shown in B. The tryptic peptides are numbered
and displayed with the corresponding se-
quences. C: Western blot analysis verified that
CK1 binds to MPO. HUVEC whole cell lysates
were incubated with purified MPO and passed
over a monoclonal MPO-specific antibody im-
mobilized on Aminolink Plus coupling gel. The
proteins eluted from the beads were subjected
to SDS-PAGE and Western blot analysis using
CK1-specific antibody. E1, E2, and E3 are se-
quential elution fractions from the beads. D: In
vitro mixing of purified proteins resulted in the
binding of MPO to CK1 but not to a control
recombinant protein (BMP7). Western blot anal-
ysis (IB) of immunopurified complexes (IP) in-
dicated that an anti-CK1 antibody (Ab) immu-
noprecipitated MPO but only when complexed
with CK1. MPO does not bind the control re-
combinant protein demonstrating the specificity
of the MPO-CK1 interaction. E: Sandwich
ELISAs: the different shapes represent the anti-
body used to detect MPO binding. Solid black
indicates the ELISA well was coated with a CK1
antibody, and open shape indicates the well was
coated with normal IgG. Antibody-captured
CK1 was incubated with purified MPO, recom-
binant MPO, or purified mouse MPO. Results
show that purified MPO was detected by the
monoclonal MPO antibody, but this antibody
did not react with recombinant MPO or mouse
MPO. Anti-MPO antibodies from three patients
with anti-neutrophil cytoplasmic autoantibody
disease (MPO-ANCA) recognized the CK1-MPO
complex with all three forms of MPO protein. F:
CK1 captures MPO directly from human plasma.
ELISA wells were coated with either anti-CK1
antibody or normal IgG. CK1 was then captured
and incubated with or without MPO in increas-
ing amounts of plasma drawn from two healthy
volunteers (V1 and V2).
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dithiothreitol and 30 mmol/L Tris-HCl, pH 7.4, for 1.5 hours
at 37°C. After cooling the tubes to room temperature,
plasma kallikrein was added to the reaction at 50 nmol/L for
25 minutes, and kallikrein activity was stopped with 0.5
mol/L di-isopropylfluorophosphate. The samples were
deproteinized using reagents provided with the Dainippon
MARKIT-M bradykinin ELISA kit and analyzed for bradykinin
release using Bachem Peninsula Laboratory’s (San Carlos,
CA) bradykinin EIA kit as per the manufacturer’s instruc-
tions. The unknown values were determined using a five-
point standard curve with an R2 value of 0.90.
Results
Identification of CK1 and CK9 as Endothelial
MPO-Binding Proteins
To identify endothelial cell surface proteins that bind MPO,
purified MPO was incubated with HUVEC membrane ly-
sates, and subsequent complexes were immunopurified
using an anti-MPO antibody. For comparison, proteinase 3,
also a cationic neutrophil granule protein, was added to an
aliquot of endothelial lysates and analyzed for binding part-
ners in parallel. Two proteins were identified that specifically
bound MPO and not proteinase 3 under these conditions
(Figure 1A). Matrix-assisted laser desorption ionization/time
of flight analysis de-termined these to be CK1 (67 kd) and
CK9 (62 kd) (Figure 1B).
CK1 was verified to physically bind MPO using an
anti-MPO affinity column to capture CK1 in complex with
MPO in the context of HUVEC protein lysates. Western
blot analysis showed CK1 specifically eluted with MPO
(Figure 1C). Mixing of purified MPO and CK1 further
confirmed the specificity of this interaction (Figure 1D).
MPO specifically bound CK1 whereas a negative-control
recombinant protein did not.
We next examined whether the interaction of MPO and
CK1 was limited to native human MPO and, moreover,
Figure 2. MPO and CK1 co-localize in living cells. A: EA.hy926 cells were incubated with MPO in serum-free medium. MPO was detected with the DAKO mouse
anti-MPO antibody, and CK1 was detected using a polyclonal anti-CK1 antibody. The yellow foci in the merged image indicate areas of co-localized CK1 and MPO.
B and C: HUVECs were also exposed to MPO in serum-free (B) or serum-containing (C) medium. MPO was labeled in this experiment with a mouse MPO antibody
from Abcam. CK1 was labeled with the same polyclonal antibody used in A. Widespread co-localization was noted in both conditions. D: Negative control for
the CK1 label on HUVECs (anti-rabbit secondary antibody only). E: Negative control for the MPO label on HUVECs (cells not treated with MPO but exposed to
the anti-MPO antibody and its corresponding secondary antibody). Original magnifications, 60.
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whether the complex was detectable using human anti-
MPO antibodies from patients with MPO-specific autoan-
tibodies.19 Sandwich ELISAs demonstrated that CK1
complexed with human native MPO, recombinant human
MPO, and native mouse MPO. MPO was detected only
when an anti-CK1 antibody was present to capture CK1
as compared with when a normal rabbit IgG was used as
the capture antibody (Figure 1E). The mouse anti-human
MPO antibody reacted with only the native MPO protein.
MPO interacts with several blood proteins such as
ceruloplasmin (its natural inhibitor), albumin, and the li-
poprotein apo-a1.20–22 The above studies were per-
formed in total cell lysates or in serum-free buffer to test
specificity. We asked if the MPO-CK1 interaction was
influenced by the presence of plasma proteins, as found
in an in vivo environment. In a competition assay, purified
MPO binding to immobilized CK1 was slightly competed
away by addition of plasma from volunteer 1 and satu-
rated at 25% plasma (Figure 1F). This effect was more
pronounced in volunteer 2 but saturated at 50%. In par-
allel, plasma was added to immobilized CK1 without
exogenously added MPO to determine whether circulat-
ing plasma MPO would bind. Free MPO in plasma bound
CK1, and interestingly, binding was maximal at the con-
centration coinciding with the saturation point with ex-
cess added MPO, indicating all available CK1 was
complexed.
To test this interaction at the cellular level, cells ex-
pressing surface CK1 were treated with MPO in the ab-
sence or presence of plasma and analyzed for the ability
of these proteins to co-localize. By immunofluorescence
microscopy, MPO co-localized with CK1 expressed on
EA.hy926 cells and on HUVECs (Figure 2). Widespread
co-localization was noted in HUVECs on the cell surface
and intracellularly in both the absence and presence of
serum (2%). Based on this data, MPO binding to CK1 is
highly likely to occur in vessels.
Internalization of MPO by Endothelial Cells Is
Blocked by Interfering with the MPO-CK1
Interaction
To test whether CK1 participates in the uptake of MPO,
we performed a blocking experiment using anti-CK1 an-
tibodies. After antibody treatment, cells were analyzed for
uptake of added MPO by flow cytometry. Experimental
design included a trypsinization step to remove residual
MPO not internalized by the cells. MPO uptake was re-
duced in the presence of anti-CK1 antibodies but not IgG
controls (Figure 3). Blocking of MPO internalization was
concentration-dependent, ie, saturation of the system
with MPO overwhelmed the antibody blocking effects
(Figure 3A). A blocking mix consisting of a polyclonal
goat anti-CK1 antibody and FXII reduced the percentage
of MPO-positive EA.hy926 cells from 42.1 to 6.1% when
the cells were treated with 2 g/ml MPO but did not block
when treated with 5 g/ml MPO. Similar results were
obtained when a monoclonal antibody specific for type II
cytokeratins was used as a blocking antibody on
HUVECs. Pretreatment with this antibody resulted in more
than a 50% decrease in the number of MPO-positive cells
(Figure 3B). This monoclonal antibody was used to block
CK1 on EA.hy926 cells; however, in this experiment nor-
mal mouse IgG was tested to assure that the mouse IgG,
in general, was not responsible for blocking MPO. The
CK antibody decreased the number of MPO-positive
cells from 33% (with the normal mouse IgG) to 12.7%.
MPO Directly Interacts with HK
To investigate potential effects of MPO binding to CK1 on
vascular processes, we asked if MPO would compete
with HK for binding to CK1, because HK is known to also
bind CK1.23 Rather than compete for CK1 binding, a
more than fivefold increase in binding of biotinylated HK
was observed in the presence of MPO (50-fold excess),
whereas the controls using a 50-fold excess of unlabeled
HK blocked biotinylated HK binding by 40% (Figure 4A).
Moreover, by immunofluorescence microscopy, MPO
and HK were found to co-localize at the surface mem-
brane and in the cytoplasm of endothelial cells (Figure
Figure 3. Internalization of MPO by endothelial cells is reduced by blocking
the MPO and CK1 interaction. Experiments are flow cytometry analyses of
endothelial cells labeled with a polyclonal anti-MPO antibody. A: EA.hy926
cells were pretreated with a CK1-blocking mix consisting of factor XII (FXII)
and a goat anti-CK1 antibody (CK Ab) raised against a kininogen-binding site
of CK1. Cells were then exposed to 2 or 5 g/ml MPO for 10 minutes. B:
HUVECs were pretreated with a pan-CK (pCK Ab) antibody and then 2
g/ml MPO was added for 10 minutes. C: EA.hy926 cells were pretreated
with either a pan-CK (pCK Ab) antibody or normal mouse IgG before 0.5
g/ml MPO was added for 10 minutes. FITC, fluorescein isothiocyanate; FSC,
forward scatter.
MPO Modulates Vasoregulatory Systems 355
AJP July 2007, Vol. 171, No. 1
4B). We next asked if enhanced binding could be attrib-
utable to a direct interaction between HK and MPO. Data
from a direct ELISA (Figure 5A) and from a capture ELISA
(Figure 5, B and C) verify that MPO and HK have the
capability to physically interact. Importantly, we also
showed that immobilized MPO bound kininogen from
plasma (Figure 5D), thus demonstrating that this interac-
tion is favored in a physiological matrix.
MPO Interferes with the Plasma Kallikrein-Kinin
System
To further explore MPO-mediated perturbations of the
plasma kallikrein-kinin pathway, we tested whether MPO
affected bradykinin production. We hypothesized that
MPO binding to HK would interfere with its cleavage by
kallikrein to produce bradykinin. Bradykinin production
from HK by plasma kallikrein was monitored in an in vitro
system with and without MPO. The results indicate that a
10-fold molar excess of MPO (500 nmol/L) to HK reduced
bradykinin production by 30% compared with equimolar
concentrations (50 nmol/L) (Figure 6A). The data indicate
that MPO binding to HK physically hinders the accessi-
bility of the kallikrein cleavage site on HK. We next asked
if MPO’s peroxidase function would influence bradykinin
production. The data indicate that when hydrogen per-
oxide (H2O2), the substrate of MPO, is present, inhibition
of bradykinin production is enhanced showing a signifi-
cant reduction at 250 nmol/L (Figure 6B) versus 500
nmol/L MPO without H2O2. Supporting that the conver-
sion of H2O2 and Cl
 to hypochlorous acid by MPO was
involved, the addition of catalase, an H2O2 scavenger,
reversed this effect (Figure 6C).
Effects of HOCl on Kallikrein and HK
HOCl, an antimicrobial oxidant produced by MPO, has
long been implicated in the pathology of inflammation
because it readily reacts with, and alters, proteins and
their functions.2 Thus, proteins in close proximity to
MPO could be affected by MPO-produced HOCl. We
first evaluated the effects of HOCl on the protease
activity of plasma kallikrein, using a colorimetric activ-
ity assay. Kallikrein activity was inhibited 50% at an
80-fold molar excess of HOCl to kallikrein and com-
pletely inhibited at a 200-fold excess (Figure 7A). A
20-fold molar excess of L-methionine to HOCl
quenched its oxidant activity2 because thiols and
Figure 4. MPO enhances kininogen binding to endothelial cells and the proteins co-localize on the endo-
thelial cell surface and intracellularly. A: MPO enhances kininogen binding. HUVECs were treated with
biotinylated high molecular weight kininogen (bHK) either alone or in the presence of a 50-fold molar excess
of unlabeled high molecular weight kininogen (uHK) or MPO for 30 minutes at 37°C. Bound bHK was
detected using alkaline phosphatase-conjugated streptavidin. Unlabeled HK competed with bHK binding
resulting in 50% less bHK protein bound. MPO enhanced bHK binding by 5.35-fold. B–E: MPO and kininogen
co-localize in/on endothelial cells. HUVECs were either treated with bHK and purified MPO (B–D) or
protein-free medium. The cells were labeled using both Alexa Fluor 488-conjugated streptavidin (B) and an
anti-MPO antibody with corresponding Alexa Fluor 568 secondary antibody (C). D: The merged image of B
and C showing a high degree of co-localization between MPO and bHK. The merged image of cells that were
treated with protein-free medium is shown in E. Original magnifications, 60.
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thioether groups of methionine are the most reactive
substrates for HOCl oxidation.
Kininogens oxidized by chloramines (stable break-
down products of HOCl) cannot bind prekallikrein or be
cleaved by kallikrein, an effect attributed to a modification
of the critical Met-361 residue adjacent to the internal
kinin sequence in kininogen to methionine sulfoxide.24,25
HOCl can mediate this same methionine-specific chem-
istry; thus we hypothesized HOCl would oxidize HK pre-
venting bradykinin release by kallikrein.26,27 The addition
of HOCl to HK inhibits bradykinin production in a dose-
dependent manner (Figure 7B). The addition of PilB, a
methionine sulfoxide reductase, reversed the decrease in
bradykinin production and verified that an HOCl-oxidized
methionine was responsible for this reduction.
Discussion
MPO has long been viewed to function primarily as a
bactericidal enzyme. A new paradigm presented here
extends this perspective and suggests that MPO is
profoundly involved in the regulation of cellular ho-
meostasis, and may play a central role in the regulation
of vasodilatation through direct interactions with
components of the kallikrein-kininogen system (dia-
grammed in Figure 8). We propose that in the inflam-
matory microenvironment, MPO is internalized by en-
dothelial cells through a direct interaction with the
endothelial surface protein CK1 (Figure 8A), known as
a scaffold for the plasma kallikrein-kinin system.13,16
CK1 seems to tether MPO into close proximity of HK,
and the two proteins are internalized in complex (Fig-
ure 8C). Moreover, MPO and HK form a complex such
that blocks the HK site normally cleaved by kallikrein
(Figure 8D). In addition, MPO’s peroxidase activity
causes oxidation and inactivation of HK protein (Figure
8E) and inactivates plasma kallikrein’s activity (Figure
8F). The end result is a reduction in bradykinin libera-
tion from HK (Figure 8G). Manipulations of bradykinin
levels at sites of inflammation could have profound
effects on vascular tone and other mediator functions
of bradykinin.
Of central importance is the finding that CK1 facili-
tates MPO internalization by endothelial cells. This is in
concordance with reports that MPO uptake is energy-
dependent, a characteristic of receptor-mediated en-
docytosis.12 Cytokeratins are typically thought of as
Figure 5. MPO binds kininogen. A: Direct ELISA: column 1: biotinylated kinino-
gen (bHK) binds immobilized MPO but not bovine serum albumin as detected
by alkaline phosphatase-conjugated streptavidin; column 2: bHK binding is
reduced in the presence of excess unlabeled kininogen (uHK); column 3:
unlabeled kininogen alone was negative. B: Sandwich ELISA: further validation
of the direct interaction between MPO and kininogen. Column 1: monoclonal
MPO antibody-captured MPO binds bHK as detected by alkaline phosphatase-
conjugated streptavidin; column 2: competition of bHK binding in the presence
of excess uHK; column 3: unlabeled kininogen alone was negative. Shown are
the averaged results of three independent trials  SDs. C: Sandwich ELISA:
validation using a second MPO antibody. Column 1: polyclonal MPO antibody-
captured MPO binds bHK as detected by alkaline phosphatase-conjugated
streptavidin; column 2: competition of bHK binding in the presence of excess
uHK; column 3: unlabeled kininogen alone was negative. Shown are the results
of three independent trials  SDs. D: MPO captures bHK from plasma. HK-
depleted plasma was replenished with bHK to physiological levels. Immobilized
MPO was used as bait to capture bHK from plasma. Shown are the results (with
SE bars) of three independent experiments.
Figure 6. MPO interferes with the plasma kallikrein-kininogen system: bradykinin production is diminished. A: MPO interfered with bradykinin production
through steric hindrance at high concentrations. Shown are the results of four independent experiments measuring the bradykinin liberated from 50 nmol/L HK
in the presence of MPO. B: Provided with its substrate (H2O2), MPO affects bradykinin production at lower concentrations. Shown are the results of three
independent experiments. C: The enzymatic activity of MPO (conversion of H2O2 to HOCl) hinders bradykinin production, which is rescued in the presence of
catalase. Shown are the results of three independent experiments.
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structural intermediate filaments, although descriptions
of the functions of CK1 in endothelial cells imply that it
is more than merely structural. CK1 functions as part of
the cells’ environmental response pathways sensitized
to oxidative stress; endothelial CK1 surface protein
expression is up-regulated in such conditions.16,28 Al-
though this is the first report of a specific endothelial
MPO-binding protein, multiple groups have investi-
gated the entry of free MPO into endothelial cells. In
our study, internalized MPO was not exclusively local-
ized to CK1, suggesting other possible mechanisms
for cell association and trafficking of MPO. Cell surface
glycosaminoglycans have been implicated in MPO in-
ternalization.12 In addition, MPO binds to albumin
through both sequence- and charge-specific mecha-
nisms; the albumin-bound MPO is nonspecifically in-
ternalized by albumin-binding proteins.21 However, our
group and others have observed substantial MPO in-
ternalization in albumin-free conditions, supporting
CK1 binding as a mode of entry.
MPO, being highly cationic, is often argued to interact
with the endothelium solely through charge-based inter-
actions. The mechanism through which CK1 and MPO
interact is yet to be determined. In light of the reports that
HK is not internalized when bound to CK1 through its
cationic domain 5, we would argue that internalization of
CK1-bound MPO is unique and specific.29,30 This would
be fundamentally different from mechanisms mediating
MPO’s adherence to endothelial cell-surface glycosami-
noglycans or its internalization coupled to albumin.
We questioned whether MPO and HK reside on CK1
together or whether they compete for binding. The data
support cooperative binding on cells, which would tether
MPO and HK into close proximity. For reasons yet to be
determined, MPO caused a substantial increase in cell-
bound HK. One speculation is that MPO is transporting
HK to additional sites for binding; MPO can bind through
both CK1-dependent and -independent interactions. It is
tempting to speculate that investigators will find addi-
tional situations in which MPO and HK functionally over-
Figure 7. Hypochlorous acid (HOCl) inhibits bradykinin production. A: The proteolytic activity of kallikrein is abolished by HOCl dose-dependently but is
protected when HOCl is quenched with L-methionine (20-fold molar excess). Shown are the results (with SDs) of three separate experiments. B: HK is oxidized
by HOCl, resulting in a product uncleavable by active kallikrein. HK was pretreated with increasing concentrations of HOCl. A 20-fold excess of L-methionine was
added (20 minutes) before the addition of active kallikrein. Bradykinin production was assessed by ELISA. Shown are the results from four separate experiments.
C: HOCl inactivates kininogen by oxidizing a critical methionine residue. HOCl-oxidized HK was treated with a methionine sulfoxide reductase (PilB), and the
inhibition of bradykinin production was reversed. DTT, dithiothreitol.
Figure 8. Proposed schematic for the interactions of MPO with endothelial cells and the plasma kallikrein-kininogen system. When a neutrophil releases its granule
constituents and oxygen radicals at sites of inflammation, MPO can leak into the lumen of the vessel. A: Endothelial cells bind and internalize MPO, in part through
interactions with the cell-surface protein CK1; MPO and CK1 enter the cells in complex. B: MPO can also enter cells through other mechanisms that have yet to be fully
characterized. C–F: MPO can modulate the action of the plasma kallikrein-kininogen system. c: MPO associates directly with high molecular weight kininogen (HK) and
increases the amount of HK bound to the cells; this complex appears to internalize. D: When MPO and kininogen are coupled, kallikrein is unable to cleave HK. MPO
uses the hydrogen peroxide generated during a neutrophil’s respiratory burst to oxidize chloride and produce hypochlorous acid (represented by the yellow asterisk).
E: Hypochlorous acid can oxidize and inactivate HK by altering kallikrein’s cleavage site (F), as well as abrogate the protease activity of kallikrein. G: In the absence of
MPO, endothelial surface proteins including CK1 bind circulating high molecular weight kininogen. Plasma kallikrein subsequently cleaves bradykinin (small red circle
with B) from kininogen; bradykinin then binds to specific endothelial receptors to induce nitric oxide generation.
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lap. For example, it was reported that MPO and HK
individually bind CD11b/CD18 integrin, and interestingly,
the outcomes were functionally opposing.31–33
The ultimate biological mediator produced by the
plasma kallikrein-kinin system is the vasoactive peptide
bradykinin, which is cleaved from HK by kallikrein. Bra-
dykinin binds at least two endothelial receptors to induce
a hypotensive and anti-thrombotic state by stimulating
endothelial nitric oxide production, prostacyclin synthe-
sis, and tissue plasminogen activator release.23,34,35 Al-
though MPO increases HK bound to endothelial cells, we
do not believe this augmentation correlates with in-
creased bradykinin production based on our studies. It
may be that MPO binding and internalization of HK
serves to sequester HK from kallikrein and hinder HK’s
effector functions in the inflammatory milieu. Beyond the
physical interference of MPO with the HK-kallikrein inter-
action, there was strong evidence that protein damage
caused by the methionine-specific oxidizing agents pro-
duced by MPO could be responsible for decreased bra-
dykinin production.26,27 There was a direct effect of bio-
logically relevant concentrations of HOCl on kallikrein
protease activity, and the oxidation of HK rendered it
resistant to kallikrein proteolysis. HOCl concentrations
less than 15 mol/L are sublethal, whereas activation of
the endothelial apoptosis machinery begins at a 30 to 50
mol/L dose, and oncotic cell death is provoked at more
than 100 mol/L.36 The data show that even sublethal
concentrations of HOCl overtly affect the ability of this
system to produce bradykinin, and doses beyond 25
mol/L totally inhibited bradykinin production (not
shown). HOCl is a highly reactive oxidant, so the proxim-
ity of MPO to HK resulting from their direct interaction and
their shared interaction with CK1 could be very important
when considering these experimental results.2
During an acute and chronic inflammatory state, MPO is
released into the vessel and is functional, based on pub-
lished studies demonstrating chlorotyrosine in vessel
walls.37 Only MPO can mediate this chemistry under phys-
iological conditions. Given the large amount of MPO per
neutrophil (5% of the dry weight), the large number of neu-
trophils infiltrating during acute infection and inflammation,
and the altered flow in vessels associated with procoagu-
lant activity, we propose that concentrations of MPO in the
inflammatory milieu can approach the 500 mmol/L range
used in these studies.38 Furthermore, in this microenviron-
ment the data indicate the potential for MPO-kininogen in-
teractions to interfere with the kininogen-kallikrein process.
The effects of MPO’s enzymatic activity could be even more
pronounced than we are reporting if in fact nitration of
tyrosine residues affects kininogen processing.12,39 MPO
can mediate tyrosine nitration in inflammatory conditions
through a reaction with nitrite, a stable end-product of nitric
oxide metabolism. A hydrogen peroxide-dependent reac-
tion, nitrite is oxidized by MPO to form the nitrogen dioxide
radical, a species capable of nitrating both free and protein-
bound tyrosines.40,41 Such reactions have been associated
with the inactivation of endothelial angiotensin-converting
enzyme as well as the structural alteration of endothelial
matrix-associated fibronectin.12,41,42
Previous studies showed that MPO remains active after
internalization and catalytically consumes NO, thereby
limiting the endothelial vasodilatory response.8 In com-
parison, our work unveils a mechanism whereby MPO
may prevent endothelial NO generation in the inflamma-
tory milieu by limiting the production of bradykinin, the
most potent known inducer of endothelial NO.
A limitation of these studies is the lack of an in vivo or ex
vivo model to demonstrate that MPO can interfere with bra-
dykinin production and thus impair vascular function. Al-
though observed in a cellular system, it is difficult to extrap-
olate the consequences of the MPO and CK1 interaction to
the inflamed tissue environment. This question will be a
focus of future studies. Another point that needs further
exploration is the composition of the internalized CK1, MPO,
and/or HK complexes. Because of limitations in available
reagents, this could not be performed herein.
In summary, CK1 is an endothelial receptor that aids in
the internalization of MPO. MPO also directly interacts
with HK, which also binds CK1 protein. The products of
MPO’s enzymatic activity can oxidize and inactivate both
HK and plasma kallikrein. The collective interactions be-
tween MPO and the plasma kallikrein-kinin system result
in a decrease in bradykinin production. Whether the par-
adigm discovered here is a normal process of an inflam-
matory response or whether it is a pathophysiological
mediator of organ injury is yet to be determined. It may be
that leakage of small amounts of MPO localized at the
vessel wall play a role that is ultimately beneficial to the
host. The converse may be true when MPO is released in
excess quantities during systemic inflammation. Regard-
less, the importance of MPO in vascular biology is further
demonstrated by these studies.
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